TB treatment: latest news

TB treatment resources

TB treatment features

TB treatment in your own words

TB treatment news from aidsmap

More news

TB treatment news selected from other sources

  • Ukraine: Concurrent treatment for HIV/TB co-infection breaks up “deadly alliance”

    USAID funded MEASURE Evaluation to initiate an impact evaluation in Ukraine for two TB programmatic priorities: Improving integration of TB and HIV services to reduce mortality through early diagnosis and treatment for co-infected patients; and providing social support services to improve TB treatment adherence.

    30 March 2015 | Science Speaks
  • Final fight pays off, XXDR-TB & HIV patient cured

    Once an active case of extremely drug resistant (XXDR-TB) strain of tuberculosis or totally drug resistant (TDR) TB, 40-year-old Rashid Khan (name changed), has now been completely cured of his disease. Despite having total drug resistance and HIV infection, Khan got cured a few days ago. At one stage he was receiving a cocktail of 18–20 drugs between his HIV and TB regimes. But Bedaquiline made a huge difference in his treatment. He is off medicine now.

    24 March 2015 | DNAIndia
  • Lancet: Phase 2b trial results of novel TB regimen show potential to shorten treatment

    A new tuberculosis (TB) drug regimen designed to improve options for TB therapy eliminated more bacteria from sputum than standard therapy, worked for people with multi-drug-resistant (MDR) TB, and did so in a quarter of the time, according to data from a phase 2b clinical trial published today in The Lancet. These results are published just as the global phase 3 clinical trial, STAND, designed to bring this regimen through the last stage of testing, has begun. The PaMZ regimen uses pretomanid, a new drug; moxifloxacin, an established antibiotic that is experimental as a TB treatment; and pyrazinamide, an established TB drug. Twenty percent of the TB patients enrolled in NC-002 also were co-infected with HIV and the PaMZ regimen appeared to be effective independent of HIV status. See also http://www.aidsmap.com/Novel-TB-regimen-could-reduce-treatment-duration/page/2892700/

    18 March 2015 | Lancet (free registration required)
  • TB drug candidate starts Phase 1 trial — first in six years

    The enrollment of nearly 50 volunteers in the United States will launch the first randomized clinical trial of a potential  new drug to treat TB in six years, the nonprofit product development partnership TB Alliance announced Wednesday.

    20 February 2015 | Science Speaks
  • TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients

    NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment.

    27 October 2014 | TB Alliance
  • Newly identified marker helps predict tuberculosis complications in HIV patients

    An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop immune reconstitution inflammatory syndrome (IRIS).

    16 October 2014 | National Institute of Allergy and Infectious Diseases (NIAID) press release
  • In HIV/TB coinfection, initiate antiretroviral therapy early

    Earlier initiation of antiretroviral therapy (ART) significantly lowered mortality in patients with HIV and tuberculosis (TB) co-infection, despite a higher incidence of immune reconstitution inflammatory syndrome (IRIS), according to data presented at 2014 IDWeek.

    16 October 2014 | Monthly Prescribing Reference (MPR)
  • What does new drug PaMZ mean for TB and HIV treatment?

    The development of PaMZ has been hailed as a breakthrough. But what do the experts think?

    02 September 2014 | The Guardian
  • Acquired rifampicin resistance more likely in HIV-coinfected patients

    Patients with HIV and tuberculosis were more likely to develop acquired rifampicin resistance when treated with a thrice-weekly tuberculosis treatment compared with patients not coinfected with HIV, according to researchers from the National Institute for Research in Tuberculosis in India. The rate of bacteriologic failure was 4% among patients without HIV. Among patients with HIV, the rates were 9% for those not receiving ART and 5% for those receiving ART.

    02 September 2014 | Healio
  • From Rhetoric to Reality: An Analysis of Efforts to Scale Up The Response to TB-HIV

    A new research report from ACTION global health shows that joint TB-HIV activities are neglected by HIV programs and overwhelmingly carried out by TB programs, and that global guidelines to address TB-HIV have not been prioritized by leading donors and affected countries.

    22 July 2014 | ACTION
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also